Page 67 - டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda Drug Target Will Advance into Takeda s Discovery Portfolio as Part of Ongoing Collaboration News provided by Share this article Share this article CHARLOTTESVILLE, Va., Dec. 10, 2020 /PRNewswire/  HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited ( Takeda ) to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda s discovery portfolio. Using the company s REVEAL-Tx™ human disease modeling platform, HemoShear is collaborating with Takeda to identify and validate novel drug targets for treating NASH. In accordance with the collaboration agreement executed in October 2017, HemoShear will receive an undisclosed milestone payment.

United statesBrian wamhoffGareth hicksHemoshear therapeuticsTakeda pharmaceutical company limitedDiscovery unit headClinical investigationNature scientific reportsஒன்றுபட்டது மாநிலங்களில்கரேத் ஹிக்ஸ்டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவைகண்டுபிடிப்பு அலகு தலைமருத்துவ விசாரணைஇயற்கை அறிவியல் அறிக்கைகள்